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Summary The thioether phospholipid ilmofosine (BM 41 440) is a new anti-cancer drug presently undergoing phase 11 clinical trials. Because
resistance to anti-tumour drugs is a major problem in cancer treatment, we investigated the resistance of different cell lines to this compound.
Here we report that the multidrug-resistant cell lines MCF7/ADR, CCRFNCR1000, CCRF/ADR500, CEMNLB100 and HeLa cell lines
transfected with a wild-type and mutated (gly/vall85) multidrug resistance 1 gene (MDR1) are cross-resistant to ilmofosine compared with the
sensitive parental cell lines. In CEMNM-1 cells, in which the resistance is associated with an altered topoisomerase 11 gene, no cross-
resistance to ilmofosine was observed. Ilmofosine is not capable of modulating multidrug resistance and neither does it reduce the labelling
of the P-glycoprotein (P-gp) by azidopine nor alter ATPase activity significantly. The resistance to ilmofosine in multidrug-resistant
CCRFNCR1000 cells cannot be reversed by the potent multidrug resistance modifier dexniguldipine-HCI (B8509-035). A tenfold excess of
ilmofosine does not prevent the MDR-modulating effect of dexniguldipine-HCI. Treatment of cells with ilmofosine does not alter the levels of
MDR1 mRNA. Long-term treatment of an ilmofosine-resistant Meth A subline with the drug does not induce multidrug resistance, indicating
that ilmofosine does not increase the level of P-gp. Determination of the MDR2mRNA levels in the cells revealed that the resistance pattern
to ilmofosine is not correlated with the expression of this gene. It is concluded, therefore, that multidrug-resistant cells are cross-resistant to
ilmofosine and that the compound is not a substrate of Pgp. No association between the expression of the MDR2-encoded P-gp and
resistance to ilmofosine was observed. It is supposed that MDR1-associated alterations in membrane lipids cause resistance to ilmofosine.
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A major problem in the successful treatment of tumours by
chemotherapy is the selection of tumour cell populations with
intrinsic or acquired resistance to anti-cancer drugs. To develop
drugs that do not exhibit cross-resistance to that of other
compounds or that reverse resistance, it is essential to understand
the mechanisms responsible for antiproliferative activity and for
treatment failure. Phospholipid analogues are a new class of
drugs that exhibit broad antineoplastic activity (Berdel, 1991).
Miltefosine (hexadecylphosphocholine) is a licensed anti-cancer
drug for the topical treatment of skin metastases resulting from
breast cancers and lymphomas. For ilmofosine (BM 41 440, 3-
hexadecyl-mercapto-2-methoxymethyl-propyl- 1-phospho-
choline), clinical phase II trials for the treatment of several
tumours are currently under way (Berdel, 1991; Winkelmann et al,
1992). Although these drugs are used in the clinic for treatment of
patients, the mechanism of action is not fully understood. It has
been reported that phospholipid analogues interfere with normal
phospholipid metabolism, inhibit the binding of the epidermal
growth factor, inhibit protein kinase C and phospholipase C and
suppress the activation of cdc2 (Hofmann et al, 1989; Berdel,
1991; Powis et al, 1992; Hofmann et al, 1994). When considering
the clinical use ofphospholipid analogues, the following questions
need to be asked: (1) why are cells refractory to these compounds;
(2) can cells acquire resistance; and (3) is there cross-resistance to
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drugs whose efficacy has been limited by the development of
resistance? The purpose of this investigation was to obtain addi-
tional information about resistance to ilmofosine. In experimental
systems, resistance to this new compound has been observed
(Himmelmann et al, 1990; Herrmann, 1985; Petersen et al, 1992).
One mechanism causing resistance to a variety of anti-tumour
compounds is the so-called multidrug resistance, caused by
increased drug efflux frequently associated with the expression
of a 170-kDa glycoprotein (P-gp) encoded by the MDR] gene
(Gottesman and Pastan, 1993). This transporter exports preferen-
tially lipophilic compounds (Gottesman and Pastan, 1993). Thus,
P-gp-dependent multidrug resistance (MDR) could influence the
sensitivity to ilmofosine. Cross-resistance of multidrug-resistant
mouse P388/ADR and sarcoma S180/ADR cell lines to ilmofosine
has been observed previously (Himmelmann et al, 1990).
The MDR genes are members of a small, highly conserved
family that comprises two members in humans, MDR] and MDR2
(Thorgeirsson et al, 1991). Recently, it was reported that the
MDR2-encoded P-glycoprotein has an essential role in the translo-
cation ofphosphatidylcholine (Smit et al, 1993; Ruetz et al, 1994).
Ilmofosine is a phosphatidylcholine analogue in which the long
chain alkyl group is linked by a thioether bond and the f-hydroxyl
group of the glycerol has been replaced by a methoxymethyl
moiety. Because ilmofosine is an analogue ofphosphatidylcholine,
it may also be transported by the MDR2-encoded P-glycoprotein.
Thorgeirsson et al (1991) proposed that the MDR] and MDR2
genes are co-expressed. The cross-resistance of multidrug-
resistant cells to ilmofosine (Himmelmann et al, 1990) may result
from the co-expression of the MDR2 gene in multidrug-resistant,
MDRJ-overexpressing cells.
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Comprehensive studies concerning the role of MDRJ and
MDR2 in the resistance to ilmofosine are still lacking. In view of
the possible relevance for cancer treatment, it was decided to
investigate the association of the expression of the MDRJ and
MDR2 genes with cross-resistance to ilmofosine.
MATERIALS AND METHODS
Drugs
Doxorubicin, vinblastine, vincristine and colchicine were pur-
chased from Sigma Chemicals, Munich, Germany. Doxorubicin
and colchicine were dissolved in distilled water, vinblastine and
vincristine sulphate in 0.9% sodium chloride. Ilmofosine was
obtained from Boehringer Mannheim, Mannheim, Germany,
dissolved in 20 mm Tris-HCl, pH 7.4, and stored at +40C.
Dexniguldipine-HCl (B859-35; Hofmann et al, 1992) was obtained
from Byk-Gulden, Konstanz, Germany, and dissolved in dimethyl-
sulphoxide in glassware. The final concentration of the solvent in
treated cultures and controls did not exceed 0.1%, and this was
non-toxic.
Cell lines
The cell lines used in the experiments were grown in RPMI-1640
medium supplemented with 10% fetal bovine serum, 2 mm gluta-
mine, 50 units ml' penicillin and 50 jg ml-1 streptomycin in 5%
carbon dioxide. To the medium ofthe multidrug-resistant cell lines
CCRF/VCRIOOO (Kimmig et al, 1990), 1 jg of vincristine
sulphate ml', to CCRF/ADR5000 (Kimmig et al, 1990) 5 jg ml'
doxorubicin, to CEM/VLB,OO (Beck et al, 1979) 100 ng ml-
vinblastine, to HeLa-MDRI-G185 100 nM vinblastine and to HeLa-
MDR1-V185 cells 240 ng ml-' colchicine were added to stock
cultures every second week. The multidrug-resistant MDRJ-over-
expressing cell lines were obtained by transfection ofhuman HeLa
S3 (HeLa-WT) cervix carcinoma cells with a MDRJ wild-type
gene construct (HeLa-MDR1-G185) or with a mutation in codon
185 (Gly-Val, kindly provided by Dr M M Gottesman, HeLa-
MDR1-V185) (Kane et al, 1989). Following transfection, HeLa-
MDR1-G185 were grown in the presence of vinblastine (100 nM)
and HeLa-MDRl-V185 in the presence of cholchicine (240 ng
ml-'). One clone ofeach cell line was taken for further cultivation.
The wild-type and mutant genes were controlled by sequencing.
The resistance pattern to vinblastine and colchicine also reflect the
expression of the wild-type and mutant MDR] gene. In atypical
multidrug-resistant CEMNVM-1 cells, the resistance is associated
with an altered topoisomerase II gene (Danks et al, 1988). A Meth
A subline resistant to ilmofosine (MR) was obtained from the
parental sensitive cells (MS) as described (Herrmann, 1985). The
resistant subline was grown in the presence of 6jg ml -1 ilmofo-
sine, except at the time ofthe experiments.
Inhibition of cell proliferation
Dose-response curves forCCRF/CEM, CEM/VM-1,CEMNVLB,I0,
CCRFNCR1000, CCRF/5000, MR and MS cells were established
by the addition of drugs at concentrations indicated in the figures.
Following incubation in the presence ofthe drugs for72 h, the cells
were counted with an electronic counter (Coulter-Electronics,
Luton, UK). Cellular multiplication (M) was calculated by M =
(T7-T0)/(C7-C0) x 100, where C are untreated controls and T are
drug-treated cells; 0 and t equal the number ofcells at time 0 and t
(72 h) respectively.
MCF7, MCF7/ADR, HeLa-WT, HeLa-MDR1-G185 and HeLa-
MDR1-V185 cells were plated in 96-well plates. Two hours after
plating of the cells, drugs were added to the cells as indicated in
the figures and exposed continuously for 72 h. Subsequently, cell
proliferation was detected using the sulphorhodamine B assay
(Skehan et al, 1990).
Accumulation of rhodamine 123
Logarithmically growing CCRF-ADR5000 cells were washed
with phosphate-buffered saline and resupended in 1 ml (5 x 105
cells ml') of Dulbecco's modified Eagle medium without serum,
supplemented with 20 mM 3-N-morpholinopropanesulphonic acid.
The cells were incubated with dexniguldipine-HCl, ilmofosine or
a combination ofboth drugs at 370C for 30 min. After addition of
60gl (5 jg ml') ofrhodamine 123 per ml ofcell suspension, fluo-
rescence (excitation at 488 nm) was detected by a flow cytometer
Table 1 IC50 values of vinblastine, doxorubicin and ilmofosine for the different cell lines
ICSO values (resistance factor)
Cell line Vinblastine (nM) Doxorubicin (nM) llmofosine (lM)
MCF-7 5.5 155.4 7.2
MCF-7/ADR 116.9 (21.25) 1352.8 (8.70) 51.4 (7.13)
CCRF/CEM 2.0 21.6 2.8
CEMNM-1 1.7 (0.85) 153.9 (7.12) 3.1 (1.10)
CEMNLB100 169.7 (84.85) 560.0 (25.92) 8.3 (2.96)
CCRFNCR1000 492.0 (246.00) 1459.0 (67.54) 19.9 (7.10)
CCRF/ADR5000 2420 (1210.00) 846.0 (39.16) 14.3 (5.10)
HeLa-WT 7.3 231.0 9.9
HeLa-MDR1-G185 251.0 (34.38) 25650.0 (111.03) 45.5 (4.59)
HeLa-MDR1-V185 91.9 (12.58) 16080.0 (69.61) 34.1 (3.44)
IC . was obtained from dose-response curves to the drugs as described in Materials and methods. The mean of three independent experiments, in which
duplicate samples were taken within each experiment, is indicated. The resistance factor (in brackets), indicating the resistance compared with the parental cell
line, is calculated by IC50-resistant/lC50-sensitive.
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(FACStar, Becton Dickinson, Mountain View, CA, USA) at the
times indicated in Figure 3. Emission was observed with a 530/30-
nm filter and fluorescence intensity was expressed as the mean of
5000 cells gated by forward- and side-scattered light to measure
only viable and single cells (Hofmann et al, 1992).
Photoaffinity labelling with [3H]azidopine
Membranes from CCRF/CEM and CCRF/ADR5000 cells
(Kimmig et al, 1990) were prepared according to Hamada and
Tsuruo (1988). The protein concentration was determined using an
assay kit from Pierce (Rockford, IL, USA). The experiments were
performed under dim light. Thirty micrograms of protein was
incubated with 0.7 ,uCi [3H]azidopine (49 Ci mmol-', Amersham,
Little Chalfort, UK) in the presence or absence of ilmofosine in a
final volume of35 ,ul ofphosphate buffer (40 mM, pH 7.4) at room
temperature for 60 min. Subsequently, the reaction mixture was
placed on ice and irradiated with a UV lamp (CAMAG, Merck,
Darmstadt, Germany) at a distance of 8 cm for 20 min. Samples
were separated on a 4-15% polyacrylamide gel containing sodium
dodecyl sulphate (SDS) and exposed to a radiographic film.
Measurement of ATPase activity
ATPase activity of P-glycoprotein partly purified from CCRF-
ADR5000 cells was quantified as described (Doige et al, 1992).
Ouabain (2 mM) and EGTA (1 mM) was included in the assay
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bufferto inhibitNa+/K+- and Ca2+-ATPases respectively. Verapamil
was used as activating control and vanadate as inhibiting control.
Detection of MDR1 and MDR2 mRNA levels
For detection of the mRNA levels, total RNA was isolated using
RNAzol (Biotecxs Laboratories, Houston, TX, USA). Synthesis of
cDNA and amplification of the MDRI mRNA by polymerase
chain reaction was performed as described (Noonan et al, 1990).
Primers for the amplification of the MDR2 mRNA were:
2061-2083 (5'-TGT CAG AAG AGC CTT GAT GTG G-3') and
2193-2215 (5'-TGG CAA TGG CAC ATA CTG TTC C-3').
Thirty cycles were performed with a denaturation temperature of
94°C (35 s), an annealing temperature of57°C (30 s) and an exten-
sion temperature of73°C (1 min). Starting with cycle 16, the time
for synthesis was extended (5 s per cycle). 3-Microglobulin was
used to control the correct amount of RNA in the experiments
(Noonan et al, 1990). The reaction products were separated on a
10% polyacrylamide gel and stained with ethidium bromide.
RESULTS
Effects of ilmofosine on multidrug-resistant cells
As shown in Table 1,MDRJ-overexpressing MCF-7/ADR cells are
cross-resistant to ilmofosine to a similar extent as to doxorubicin
but less cross-resistant to vinblastine, compared with the parental
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Figure 1 Concomitant treatment of CCRF/CEM and CCRFNCR1000 (A) and HeLa-WT and HeLa-MDR1-V185 cells (B) with doxorubicin and ilmofosine. The
cells were exposed to the indicated concentrations of drugs or drug combinations for 72 h. Experiments were performed as described in Materials and methods.
Inhibition of cell proliferation is indicated as per cent of untreated controls (= 100%). Data represent the mean (± s.e.m.) of three independent experiments, in
which duplicate samples were taken within each experiment
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Figure 2 Inhibition of cell proliferation by dexniguldipine-HCI, ilmofosine
and a combination of both drugs. CCRFNCR1000 cells were exposed to the
indicated drugs for 72 h. The concentrations of dexniguldipine-HCI are
indicated on the upper x-axis, the concentrations of ilmofosine on the lower
x-axis. The triangles show a combination of ilmofosine doses shown on the
lower x-axis, with dexniguldipine-HCI doses shown on the upper x-axis (at a
constant ratio of 10:1). Data represent the mean values (± s.e.m.) of two
independent experiments (duplicate determinations within each experiment)
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Figure 4 Interaction of ilmofosine with P-glycoprotein. Photoincorporation of
[3H]azidopine into P-glycoprotein enriched membranes of multidrug-resistant
CCRF/ADR5000 and sensitive CCRF/CEM cells was measured in absence
and presence of ilmofosine. Conditions were as described in Materials and
methods. Verapamil was used as a control
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Figure 5 ATPase activity in the presence of ilmofosine. The ATPase activity
of 5 igg of protein of P-glycoprotein-enriched membranes isolated from
CCRF-ADR5000 cells was quantified as described in Materials and methods.
The activity without drugs was defined as 100%. Verapamil and vanadate
were used as positive and negative controls respectively. The ATPase activity
of P-glycoprotein isolated from sensitive CCRF-CEM was below 20%. The
mean of four independent experiments (n = 8, ± s.d.) is indicated
0 306
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Figure 3 Time dependence of the intracellular accumulation of rhodamine
123. CCRF-DOX5000 cells were preincubated for 30 min with the indicated
concentrations of drugs. Fluorescence of the intracellular rhodamine 123 was
detected by flow cytometry as described in Materials and methods at the
indicated times after rhodamine addition. The intracellular accumulation of
rhodamine 123 in sensitive cells is in the range of the dexniguldipine-HCI-
treated resistant cells (Hofmann et al, 1992). The mean of two independent
determinations is indicated
cell line. CEM/VLBCoO, CCRF/VCR1000 and CCRF-ADR5000
cells exhibit modest cross-resistance to ilmofosine (Table 1). In
CEMIVM-1 cells, multidrug resistance is not due to expression of
MDRI but is associated with an alteration in the topoisomerase II
gene (Danks et al, 1988). These cells are resistant to the topoiso-
merase inhibitor doxorubicin but not to vinblastine or ilmofosine
(Table 1). These results illustrate that resistance to ilmofosine
seems to be associated with multidrug resistance elicited by the P-
glycoprotein. In order to substantiate this assumption, cells trans-
fected with the MDRJ-gene were used. Human HeLa cells
transfected with a wild-type MDRJ gene (HeLa-MDR1-G185) or a
Gly/Val mutation in position 185 (HeLa-MDRI-V185) are
multidrug resistant and exhibit cross-resistance to ilmofosine, indi-
cating that expression of the MDRJ gene is sufficient to cause
cross-resistance to ilmofosine (Table 1). The extent ofresistance to
ilmofosine in MCF-7/ADR is similar to that to doxorubicin (resis-
tance factor 7.13 and 8.7 respectively); in the other resistant cell
lines tested, the resistance to ilmofosine is considerably lower than
to vinblastine and doxorubicin (Table 1).
Combinations of ilmofosine with doxorubicin
The correlation between multidrug resistance and resistance to
ilmofosine suggests that the phospholipid analogue may be a
substrate for the MDRJ-encoded P-glycoprotein. Ifthis is the case,
ilmofosine should act as a modulator of the P-glycoprotein
activity. For this reason, we tried to reverse multidrug resistance.
A combination of different concentrations of doxorubicin and
ilmofosine in CCRF/CEM and CCRFNCR1000 is shown in
Figure IA. No reversal of resistance could be observed. In addi-
tion, in the MDRJ-transfected cell line (HeLa-MDRl-V185), also
no reversal of doxorubicin resistance was achieveable with ilmo-
fosine (Figure 1B). The resistance ofdoxorubicin could also not be
reversed by ilmofosine in CEM/VLBIoO and MCF7/ADR cells
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Figure 6 Effect of ilmofosine on cell multiplication of sensitive and resistant
Meth A cells. Cell multiplication was determined after 72 h continuous
incubation with the indicated concentrations of ilmofosine as described in
Materials and methods. The mean of three independent experiments, in
which duplicate determinations were taken within each experiment (± s.e.m.),
is indicated
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Figure 7 Inhibition of cell proliferation of MS and MR cells by vinblastine.
The cells were continuously exposed to vinblastine for 72 h and counted by
an electronic counter. Mean values (± s.e.m.) of two independent
experiments (duplicate determinations within each assay) are indicated
(data not shown). Ilmofosine was also not able to reverse the
resistance to vinblastine in CCRF/VCR1000, HeLa-MDR1,
CEM/VLBioo and MCF7/DOX cells (data not shown).
Combination of ilmofosine with the multidrug
resistance-reversing agent dexniguldipine-HCI
If cross-resistance of multidrug-resistant cells to ilmofosine is
caused by an increased export ofilmofosine by P-glycoprotein, the
resistance to the compound should be reversible by a MDR-modu-
lating agent. Ithas been shown previously that dexniguldipine-HCl
(B8509-035) is approximately ten times more potent in reversing
multidrug resistance than verapamil. To reverse multidrug resis-
tance completely, 0.1 tM of the compound is sufficient (Hofmann
et al, 1992). In order to investigate whether inhibition of P-glyco-
protein by dexniguldipine-HCl increases the antiproliferative
activity ofilmofosine, we treated CCRF/VCR1000 cells with both
drugs concomitantly. Figure 2 shows the antiproliferative effects of
ilmofosine (5-75 gM), dexniguldipine-HCl (0.5-7.5 gM) and a
combination of both drugs (constant ratio 10:1). Dexniguldipine-
HCl is not able to enhance the antiproliferative activity of ilmofo-
sine in multidrug-resistant CCRF/VCR1000 cells at any of the
concentrations applied, indicating again that ilmofosine seems not
to be a substrate ofP-glycoprotein.
Effects of ilmofosine on P-glycoprotein
In order to substantiate the conclusion that the resistance of
MDRJ-overexpressing cells to ilmofosine is not due to an
enhanced P-glycoprotein-catalysed efflux of the phospholipid
analogue, the interaction of ilmofosine with the P-glycoprotein
was investigated. The fluorescent dye rhodamine 123 has been
shown to act as an excellent substrate for the P-glycoprotein
(Hofmann et al, 1992). Figure 3 demonstrates that dexniguldipine-
HCl increases the intracellular level of rhodamine 123 by
inhibiting the P-glycoprotein mediated efflux. The level of intra-
cellular rhodamine after treatment with 1 ,UM dexniguldipine-HCl
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Figure 8 Expression of the MDR1 gene following treatment with ilmofosine. The MDR1 mRNA levels in CCRF/CEM and CCRFNCR1000 cells were
determined by polymerase chain reaction before and after treatment with ilmofosine for the times indicated. The polymerase chain reaction was performed with
1, 10 and 100 ng of cDNA to avoid a plateau of MDR1 in VCR/1000 cells. J3-microglobulin was used as a control for the correct amount of RNA used in the
experiment
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Figure 9 Detection of the MDR1 and MDR2 mRNA levels by polymerase chain reaction. PCR was performed as described in Materials and methods and in
the legend to Figure 8
is in the range ofsensitive cells (Hofmann et al, 1992). In contrast,
ilmofosine does not exhibit a significant effect on rhodamine
accumulation (Figure 3). A combination of ilmofosine with
dexniguldipine-HCl enhances the effect of dexniguldipine on
rhodamine accumulation (Figure 3). This result seems to indicate
an enhanced accessibility of P-glycoprotein to the dexniguldipine
action (and not competition for the binding site), probably because
of an increased membrane fluidity under the influence of ilmofo-
sine. The data also demonstrate that the MDR-modulating potency
of dexniguldipine-HCl is not reduced in the presence of a tenfold
molar excess of the phospholipid analogue. On the contrary, there
is a potentiation ofthe inhibitory effect ofdexniguldipine-HCl.
That ilmofosine indeed enhances the accessibility of P-glyco-
protein ligands is also evident from photoaffinity studies. The
dihydropyridine azidopine is a well-established photoaffinity label
for P-glycoprotein. Figure 4 demonstrates that there is no competi-
tion between ilmofosine and [3H]azidopine. On the contrary,
ilmofosine in this experiment also renders P-glycoprotein more
accessable and increases the binding of azidopine. Furthermore,
no significant alteration of the P-glycoprotein ATPase activity by
ilmofosine could be detected, also indicating no direct interaction
of ilmofosine with P-glycoprotein (Figure 5).
Resistance of Meth A cells
As described above, multidrug-resistant cells are cross-resistant to
ilmofosine. The question was whether cells selected for resistance
to ilmofosine are multidrug resistant and therefore cross-resistant
to drugs transported by P-glycoprotein. In order to investigate this
question, we used murine Meth A fibrosarcoma cells sensitive and
resistant to ilmofosine. The resistance was obtained by addition of
increasing concentrations of the phospholipid analogue ET-18-
OCH3 (1-octadecyl-2-0-rac-glyero-3-phosphocholine) (Petersen
et al, 1992). The cells are cross-resistant to ilmofosine and have
been grown in the presence of 6,g ml-' (equivalent to 11.7 gM)
ilmofosine for long periods of time. Dose-response curves of the
sensitive and resistant cell lines are shown in Figure 6. Both cell
lines exhibit similar sensitivity to vinblastine (Figure 7), indicating
that long-term treatment with ilmofosine does not lead to a
multidrug-resistant phenotype. Also short-term treatment with the
compound does not increase the MDRJ mRNA levels, as shown in
Figure 8.
Expression of the MDR2 gene
It has been reported recently that the MDR2-encoded P-glyco-
protein transports phosphatidylcholine out of the cell (Smit et al,
1993; Ruetz et al, 1994). For this reason, we investigated whether
this gene is involved in the resistance to ilmofosine by detection of
the MDRJ and MDR2 mRNA levels. In Figure 9, the amount of
MDRJ mRNA and that of the MDR2 mRNA in the different cell
lines is shown. In sensitive HeLa-WT and resistant MDRJ-over-
expressing HeLa cells, no MDR2 expression was observed. Both
MCF-7 cell lines exhibit similar levels of MDR2 mRNA (Figure
9). These results argue against a role ofMDR2 in the resistance to
ilmofosine.
DISCUSSION
Our results show that the MDRJ-overexpressing cells MCF-
7/ADR, CEM/VLB100, CCRFNVCR1000, CCRF/ADR5000 and
two HeLa cell lines transfected with MDRJ genes are cross-
resistant to ilmofosine. Although the resistance to ilmofosine is
considerably lower than to vinblastine or doxorubicin, a three- to
sevenfold resistance can cause treatmentfailure in patients. Altered
toposiomerase II-resistant CEM/VM-1 cells do not exhibit cross-
resistance to the compound. The data obtained with HeLa-MDRl-
G185 and HeLa-MDR1-V185 cells indicate that elevation of the
expression of MDRJ by transfection of the gene is sufficient to
elicit cross-resistance to ilmofosine and that no additional mecha-
nism seems to be involved. P-glycoprotein transports lipophilic
compounds out of the cell. Therefore, cross-resistance of
multidrug-resistant cells could be caused by increased efflux of
ilmofosine catalysed by the P-glycoprotein. Our data argue against
this possibility: (1) ilmofosine does not enhance the antiprolifera-
tive activity of doxorubicin (Figure lA and B) or vinblastine
(data not shown); (2) the potent P-glycoprotein modulator
dexniguldipine-HCl is not able to affect the sensitivity to
ilmofosine (Figure 2); (3) a tenfold excess of ilmofosine does
not compete with the P-glycoprotein inhibitory effect of
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dexniguldipine-HCl, as shown by the intracellular accumulation of
rhodamine 123 (Figure 3); (4) ilmofosine does not compete with
azidopine for the binding site (Figure 4); and (5) the ATPase
activity determined in presence ofilmofosine is not altered signifi-
cantly (Figure 5). This is an indication that ilmofosine does not
interact directly with the P-glycoprotein, a conclusion that has
recently also been reported by Principe et al (1994). A possible
explanation for cross-resistance of multidrug-resistant cells to
ilmofosine is that P-glycoprotein-expressing cells have an altered
lipid composition, which renders cells less susceptible to the
antiproliferative activity of ilmofosine (Endicott and Ling, 1989).
In addition, P-glycoprotein seems to be involved in the transport
of sterols from the membrane to the endoplasmic reticulum
(Metherall et al, 1996); this may lead to altered lipid composition
of membranes, leading to resistance to ilmofosine. It was reported
previously that a unique glycosphingolipid pattern is associated
with multidrug resistance in MCF7 cells (Lavie et al, 1996). Le
Moyec et al (1996) showed by nuclear magnetic resonance spec-
troscopy that cellular lipids are involved in the MDRJ-mediated
resistance to doxorubicin and taxol. Our results are consistent with
these reports. Resistance of MDRJ-expressing cells to ilmofosine
seems not to be a direct but an indirect effect of P-glycoprotein
action. MDRJ expression leads to lipid and membrane alterations,
and these alterations seem to cause resistance to ilmofosine.
It was shown that phosphatidylcholine is transported by the
MDR2-encoded P-glycoprotein (Smit et al, 1993; Ruetz et al,
1994). Because ilmofosine is a phosphatidylcholine analogue, it
could be speculated that MDR2 is responsible for differences in the
sensitivity to the compound. Our results argue against this possi-
bility (Figure 9). Thorgeirsson et al (1991) proposed a possible
mechanism for co-induction of the MDRJ and MDR2 gene. We
could not observe a co-expression of both genes in our cell lines
(Figure 9).
Ilmofosine is an inhibitor of protein kinase C (Hofmann et al,
1989). There is experimental evidence that phosphorylation of P-
glycoprotein by protein kinase C modulates the activity of the
efflux pump (Ma et al, 1991; Chambers et al, 1992; Ahmad and
Glazer, 1993). For the protein kinase C inhibitor ilmofosine, this
mechanism seems to be of minor importance because the
compound does not reduce multidrug resistance (Figure 1A and B;
data not shown). KB-8-5 cells are the only cells in which ilmofo-
sine is able to reverse multidrug resistance. These cells are also not
cross-resistant to ilmofosine (data not shown). The reason may be
that KB cells are exceptionally sensitive to phospholipid analogues
(Fleer et al, 1993).
It has been reported that modulation ofprotein kinase C activity
may alter the expression of the MDRI gene (Chaudhary and
Roninson, 1992; Sampson et al, 1993). Ilmofosine, however, does
not influence the expression ofthe MDR] gene as detected by poly-
merase chain reaction (Figure 8). Long-term exposure of cells to
ilmofosine, as shown in MR cells that are grown in the presence of
the drug, did not lead to a multidrug-resistant phenotype. As shown
in Figure 7, there is no difference in sensitivity to vinblastine in MS
and MR cells. From these experiments, it can be concluded that
treatment of patients with ilmofosine may not induce multidrug
resistance. Multidrug resistance in patients is usually in the range of
MCF7/ADR cells or lower. As shown in Table 1, the resistance of
the MCF7/ADR cell line to ilmofosine is in the same range as
doxorubicin. Therefore, the question whether expression of the
MDR phenotype in patients may influence the effects ofilmofosine
treatment in the clinic has to be addressed.
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ABBREVIATIONS
Dexniguldipine-HCl, B8509-035, (4R)-3-[4,4-diphenyl-1-
piperidinyl(propyl)]-5-methyl- 1,4-dihydro-2,6-dimethyl-4-
(3-nitrophenyl)-pyridine-3,5-dicarboxylate-hydrochloride; EGTA,
ethyleneglycol-bis(3-aminoethylether) N,N,N',N'-tetraacetic acid);
HeLa-WT, drug-sensitive HeLa wild-type cells; HeLa-MDR1-G185,
HeLa-WT cells transfected with a MDR] wild-type gene containing
a glycine in position 185; HeLa-MDR1-V185, HeLa-WT cells trans-
fected with a mutantMDR] gene containing a valine in position 185;
ilmofosine, BM 41 440, 3-hexadecyl-mercapto-2-methoxymethyl-
propyl-l-phosphocholine; MDR, multidrug resistance; MDR],
multidrug resistance gene 1; MDR2, multidrug resistance gene 2;
MS, Meth Acells sensitive to ilmofosine; MR, Meth A cells resistant
to ilmofosine; PCR, polymerase chain reaction
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